OptimizeRx Corp. (NASDAQ:OPRX) Receives $11.81 Consensus PT from Analysts

Key Points

• OptimizeRx Corp. has received a consensus rating of "Moderate Buy" from analysts, with a target price averaging $11.81.
• Recent upgrades from analysts include JMP Securities raising their price target from $14.00 to $20.00 and Zacks Research upgrading from "hold" to "strong-buy."
• Institutions hold a significant 76.47% stake in OptimizeRx, with Nisa Investment Advisors LLC increasing their stake by 600% in the second quarter.

OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) has received a consensus rating of "Moderate Buy" from the twelve analysts that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $11.8125.

A number of research firms have recently issued reports on OPRX. Stifel Nicolaus lifted their price objective on shares of OptimizeRx from $16.00 to $18.00 and gave the company a "buy" rating in a report on Friday, August 8th. Roth Capital reiterated a "buy" rating on shares of OptimizeRx in a report on Friday, August 8th. Zacks Research upgraded shares of OptimizeRx from a "hold" rating to a "strong-buy" rating in a report on Friday, September 5th. Wall Street Zen upgraded shares of OptimizeRx from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Finally, JMP Securities lifted their price objective on shares of OptimizeRx from $14.00 to $20.00 and gave the company a "market outperform" rating in a report on Monday, August 11th.

Insider Activity

In related news, Director Patrick D. Spangler sold 11,120 shares of the business's stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $17.49, for a total transaction of $194,488.80. Following the transaction, the director directly owned 44,215 shares in the company, valued at approximately $773,320.35. The trade was a 20.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of OPRX. Blair William & Co. IL increased its holdings in shares of OptimizeRx by 4.9% in the first quarter. Blair William & Co. IL now owns 631,031 shares of the company's stock valued at $5,465,000 after purchasing an additional 29,648 shares during the last quarter. Squarepoint Ops LLC increased its holdings in shares of OptimizeRx by 298.8% in the fourth quarter. Squarepoint Ops LLC now owns 41,712 shares of the company's stock valued at $203,000 after purchasing an additional 31,252 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of OptimizeRx by 47.1% in the first quarter. Janney Montgomery Scott LLC now owns 124,751 shares of the company's stock valued at $1,080,000 after purchasing an additional 39,969 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of OptimizeRx by 234.7% in the fourth quarter. Jane Street Group LLC now owns 72,454 shares of the company's stock valued at $352,000 after purchasing an additional 50,808 shares during the last quarter. Finally, Calamos Advisors LLC acquired a new position in shares of OptimizeRx in the first quarter valued at $289,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Stock Up 1.6%

OPRX stock traded up $0.28 during mid-day trading on Wednesday, hitting $17.61. 114,953 shares of the company were exchanged, compared to its average volume of 380,066. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.57 and a current ratio of 2.57. The firm has a market cap of $327.04 million, a P/E ratio of -32.68 and a beta of 1.20. The firm's 50 day simple moving average is $15.36 and its 200 day simple moving average is $11.92. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $19.25.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.